MEDMAN s.r.o.

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Psoriatic arthritis7 trials
• Psoriasis5 trials
• Rheumatoid arthritis4 trials
• Lupus (SLE)2 trials
• Sjögren's disease2 trials

Phase

• Phase 311 trials
• Phase 23 trials
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Completed5 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• AbbVie4 trials
• Janssen Research & Development, LLC4 trials
• MoonLake Immunotherapeutics AG2 trials
• Sun Pharmaceutical Industries Limited2 trials
• Anaptysbio Inc.1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

  NCT06972446· Phase 2· AbbVie· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Active, not recruiting

  Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

  NCT04991116· Phase 3· Sun Pharmaceutical Industries Limited· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

  NCT02629159· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)1 recruiting
• Psoriatic arthritis1 recruiting

Closed trials

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

  2023-504564-42-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

  NCT06073093· Phase 2· Sanofi· Source

• Completed

  Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

  NCT04314544· Phase 3· Sun Pharmaceutical Industries Limited· Source